ENTRY       D11585                      Drug
NAME        Terazosin hydrochloride anhydrous
PRODUCT
  GENERIC   TERAZOSIN (A-S Medication Solutions)
            TERAZOSIN (A-S Medication Solutions)
            TERAZOSIN (Aphena Pharma Solutions - Tennessee)
            TERAZOSIN (Aphena Pharma Solutions - Tennessee)
            TERAZOSIN (AvKARE)
            TERAZOSIN (AvPAK)
            TERAZOSIN (Bryant Ranch Prepack)
            TERAZOSIN (Bryant Ranch Prepack)
            TERAZOSIN (Jubilant Cadista Pharmaceuticals)
            TERAZOSIN (NuCare Pharmaceuticals)
            TERAZOSIN (Proficient Rx LP)
            TERAZOSIN (Proficient Rx LP)
            TERAZOSIN (Quality Care Products)
            TERAZOSIN (RedPharm Drug)
            TERAZOSIN (St. Mary's Medical Park Pharmacy)
            TERAZOSIN HYDROCHLORIDE (Aphena Pharma Solutions - Tennessee)
            TERAZOSIN HYDROCHLORIDE (Aphena Pharma Solutions - Tennessee)
            TERAZOSIN HYDROCHLORIDE (Apnar Pharma LP)
            TERAZOSIN HYDROCHLORIDE (Bryant Ranch Prepack)
            TERAZOSIN HYDROCHLORIDE (Golden State Medical Supply)
            TERAZOSIN HYDROCHLORIDE (Quality Care Products LLC)
FORMULA     C19H25N5O4. HCl
EXACT_MASS  423.1673
MOL_WEIGHT  423.8938
CLASS       Cardiovascular agent
             DG01466  Adrenergic receptor antagonist
              DG01465  alpha-Adrenergic receptor antagonist
               DG01457  alpha1-Adrenergic receptor antagonist
             DG03231  Antihypertensive
REMARK      ATC code: G04CA03
            Chemical structure group: DG00491
            Product (DG00491): D00610<JP/US> D11585<US>
EFFICACY    Antidysuria, Antihypertensive, alpha1-Adrenergic receptor antagonist
  DISEASE   Hypertension [DS:H01633]
COMMENT     Prazosin derivative
TARGET      ADRA1 [HSA:148 147 146] [KO:K04135 K04136 K04137]
  PATHWAY   hsa04022(146+147+148)  cGMP-PKG signaling pathway
            hsa04080(146+147+148)  Neuroactive ligand-receptor interaction
            hsa04261(146+147+148)  Adrenergic signaling in cardiomyocytes
            hsa04270(146+147+148)  Vascular smooth muscle contraction
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             G GENITO URINARY SYSTEM AND SEX HORMONES
              G04 UROLOGICALS
               G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
                G04CA Alpha-adrenoreceptor antagonists
                 G04CA03 Terazosin
                  D11585  Terazosin hydrochloride anhydrous &lt;US&gt;
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01466  Adrenergic receptor antagonist
               DG01465  alpha-Adrenergic receptor antagonist
                DG01457  alpha1-Adrenergic receptor antagonist
                 DG00491  Terazosin
                  D11585  Terazosin hydrochloride anhydrous
              DG03231  Antihypertensive
               DG00491  Terazosin
                D11585  Terazosin hydrochloride anhydrous
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG03231  Antihypertensive
               D11585  Terazosin hydrochloride anhydrous
            Target-based classification of drugs [BR:br08310]
             G Protein-coupled receptors
              Rhodopsin family
               Adrenaline
                ADRA1
                 D11585  Terazosin hydrochloride anhydrous &lt;US&gt;
            Drug groups [BR:br08330]
             Cardiovascular agent
              DG01466  Adrenergic receptor antagonist
               DG01465  alpha-Adrenergic receptor antagonist
                DG01457  alpha1-Adrenergic receptor antagonist
                 DG00491  Terazosin
              DG03231  Antihypertensive
               DG00491  Terazosin
DBLINKS     CAS: 63074-08-8
            PubChem: 405226452
ATOM        29
            1   C8y C    18.0600  -17.9200
            2   C8y C    18.0600  -16.5200
            3   C8x C    19.2500  -18.6200
            4   C8y C    16.8700  -18.6200
            5   N5x N    16.8700  -15.8200
            6   C8x C    19.2500  -15.8200
            7   C8y C    20.5100  -17.9200
            8   N5x N    15.6100  -17.9200
            9   N1a N    16.8700  -20.0200
            10  C8y C    15.6100  -16.5200
            11  C8y C    20.5100  -16.5200
            12  O2a O    21.7000  -18.6200
            13  N1y N    14.4200  -15.8200
            14  O2a O    21.7000  -15.8200
            15  C1a C    22.8900  -17.9200
            16  C1x C    14.4200  -14.4200
            17  C1x C    13.2300  -16.5200
            18  C1a C    22.8900  -16.5200
            19  C1x C    13.2300  -13.7200
            20  C1x C    11.9700  -15.8200
            21  N1y N    11.9700  -14.4200
            22  C5a C    10.7800  -13.7200
            23  C1y C     9.5900  -14.4200
            24  O5a O    10.7800  -12.3200
            25  C1x C     9.5900  -15.8200
            26  O2x O     8.2600  -14.0000
            27  C1x C     7.4200  -15.1200
            28  C1x C     8.2600  -16.2400
            29  X   Cl   23.4500  -12.2500
BOND        31
            1     1   2 2
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     2   6 1
            6     3   7 2
            7     4   8 2
            8     4   9 1
            9     5  10 2
            10    6  11 2
            11    7  12 1
            12   10  13 1
            13   11  14 1
            14   12  15 1
            15   13  16 1
            16   13  17 1
            17   14  18 1
            18   16  19 1
            19   17  20 1
            20   19  21 1
            21    7  11 1
            22    8  10 1
            23   20  21 1
            24   21  22 1
            25   22  23 1
            26   22  24 2
            27   23  25 1
            28   23  26 1
            29   26  27 1
            30   27  28 1
            31   25  28 1
///
